Immunome, Inc. (IMNM) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Immunome, Inc. (IMNM).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $10.20

Daily Change: -$0.26 / 2.55%

Daily Range: $9.82 - $10.90

Market Cap: $858,811,456

Daily Volume: 1,108,536

Performance Metrics

1 Week: -6.18%

1 Month: 11.02%

3 Months: 32.84%

6 Months: -16.57%

1 Year: -20.11%

YTD: -7.06%

Company Details

Employees: 118

Sector: Health technology

Industry: Biotechnology

Country:

Details

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Selected stocks

Archimedes Tech SPAC Partners II Co. (ATIIU)

D. Boral ARC Acquisition I Corp. (BCARU)

Cantor Equity Partners II, Inc. (CEPT)